Acclaro Medical builds medical aesthetic devices centered on its UltraClear® 2910 nm cold ablative fiber laser, powered by proprietary 3DIntelliPulse™ technology, and the AuraLux™ system that leverages Cool Pulse™ technology. The UltraClear platform is positioned to treat multiple skin layers with claims of improved safety across all skin types, reduced downtime, and faster healing; the company also markets 3DMIRACL™ and Laser Coring™ skin‑rejuvenation treatments. Acclaro intends to use recent financing to accelerate commercial expansion, advance product development, grow its team, and expand global market reach. The company emphasizes clinical efficacy and broader accessibility for aesthetic providers as core commercial messages. Acclaro was founded in 2018 and frames its roadmap around bringing additional pipeline products to market while scaling adoption of UltraClear and AuraLux. The business announced a material capital infusion in May 2025 to support these plans.

Total raised

$23M

Funding rounds

1

Latest round

Series B

Latest activity

May 2025